Avalo Therapeutics Inc
avalotx.comAvalo Therapeutics (NASDAQ: AVTX) is a clinical-stage biopharmaceutical company focused on developing drug candidates through partnerships and asset transactions rather than direct commercialization. The company generates no product revenue; its financial interests consist of contingent milestone payments and royalty rights tied to the clinical and commercial progress of out-licensed or divested assets. As of the 10-K filed March 23, 2026, AVTX holds milestone and royalty interests in at least two programs: AVTX-501, an aticaprant-based depression candidate licensed to Johnson and Johnson (whose depression program was discontinued as of March 2025), and AVTX-007, a drug candidate in atopic dermatitis being developed by Apollo, which met its Phase 2a primary endpoint as of September 2025. The fair value of AVTX-007 milestones and royalties was modeled on peak annual net sales of $1.7 billion in atopic dermatitis, a roughly 41% probability of success, and an estimated commercialization timeline of approximately 6.5 years. The company operates at a net loss and funds operations through financing activities.
Products & Services
AVTX-501: aticaprant-based depression candidate, licensed to Johnson and Johnson; J&J discontinued the depression program as of March 2025. AVTX-007: drug candidate in atopic dermatitis, under development by Apollo; met Phase 2a primary endpoint as of September 2025, with peak annual net sales modeled at $1.7 billion and estimated commercialization in approximately 6.5 years (per 10-K filed 2026-03-23).
Revenue Model
Contingent milestone payments and royalty rights on out-licensed drug candidates. No product revenue is disclosed in the filing excerpts. The company operates at a net loss and relies on financing activities, including private placements and warrant exercises, to fund operations.
Customers & Markets
End markets are defined by the therapeutic indications of out-licensed assets: major depressive disorder (AVTX-501, program discontinued as of March 2025) and atopic dermatitis (AVTX-007, Phase 2a stage as of September 2025). Counterparties holding development rights are Johnson and Johnson (AVTX-501) and Apollo (AVTX-007).
Geographic Exposure
Incorporated and headquartered in the United States; subject to FDA regulatory framework and BPCIA exclusivity rules. GDPR compliance obligations indicate some operational exposure to the European Economic Area. No specific revenue by geography is disclosed in the filing excerpts.
Financial Snapshot
Loading...
